

## Attorney Docket No. 06267.0085

2. (Amended) A solution according to claim 1, the pH-value of the solution being in the range of from about 3 to about 4.2.

3. (Amended) An aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, and optionally a solubility enhancing agent.

4. (Amended) A solution according to claim 3, the pH-value of the solution being in the range of from about 3 to about 4.2.

A<sup>2</sup> 5. (Amended) A solution according to claim 3, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

6. (Amended) A pharmaceutical solution, comprising  
(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,

(b) a pharmaceutically acceptable organic solvent comprising ethanol,  
(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally  
(d) a water-solubility enhancing agent.

7. (Amended) A solution according to claim 6, wherein the amount of said solvent is 90-99.9% by weight of the solution.

8. (Amended) A solution according to claim 6, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

9. (Amended) A solution according to claim 6, wherein the pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.

10. (Amended) A solution according to claim 9, wherein the pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

- A3
13. (Amended) A solution according to claim 6, comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof in an amount of 0.01-1.0% by weight,
  - (b) dehydrated ethanol in an amount of 95-99.5% by weight,
  - (c) citric acid in an amount of 0.03-0.6% by weight, and
  - (d) polyvinylpyrrolidone in an amount of 0.5-2% by weight.

14. (New) A solution according to claim 1, wherein the pH-value of the solution is about 4.5 or lower.

A4

15. (New) A solution according to claim 3, wherein the pH-value of the solution is about 4.5 or lower.

16. (New) A solution according to claim 4, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

17. (New) A solution according to claim 6, wherein the solution is an intravenous infusion concentrate.

18. (New) A solution according to claim 6, wherein the amount of said solvent is 95-99.9% by weight of the solution.

19. (New) A solution according to claim 6, wherein the amount of said organic acid is 0.01-1% by weight of the solution.

20. (New) A solution according to claim 7, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

21. (New) A solution according to claim 7, wherein the amount of said organic acid is 0.01-1% by weight of the solution.